Alcon Inc. research snapshot
ALC AI stock analysis currently reads Alcon as a global eye-care specialist with recurring demand from cataract surgery, contact lenses, dry-eye products, and surgical consumables. At the July 11, 2026 data cutoff, ALC last traded near $66.91 and its market capitalization was approximately $32.8 billion. First-quarter 2026 sales grew 10 percent reported to $2.706 billion, while management maintained 2026 constant-currency sales growth guidance of 5 percent to 7 percent. The business has durable clinical and distribution advantages, but the investment case still depends on product launches, margin execution, tariffs, currency, and disciplined capital allocation. This page is informational research only and is not investment advice.
Current price
$66.91
Market cap
$32.8 billion
AI score
68 / 100
Rating
Durable eye-care franchise with improving launches, execution and tariff risk
Trend status
Below the 52-week high with a range-bound setup pending fresh earnings and volume confirmation
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Alcon sells surgical equipment, implantables, consumables, contact lenses, and ocular-health products that support recurring eye-care demand across clinics, hospitals, optometrists, and consumers. | High |
| Moat | Clinical evidence, regulatory approvals, surgeon training, installed equipment, trusted brands, global distribution, and manufacturing know-how create switching costs, though large medical-device competitors remain active. | Medium-high |
| Management | Management is investing behind Unity, Tryptyr, surgical equipment, and Vision Care launches while returning capital through dividends and buybacks. The test is whether these investments support margins and cash generation. | Medium-high |
| Financial trend | FY2025 revenue was $10.401 billion, up 4.94 percent, with $980 million of net income and $1.728 billion of free cash flow. Q1 2026 sales rose 10 percent reported to $2.706 billion. | High |
| Valuation | At $66.91, precise checks using TTM GAAP figures indicate about 40.31x earnings, 1.49x book value, and 19.12x free cash flow per share. Core earnings are higher than GAAP earnings, so the chosen definition matters. | Medium-high |
| Technical trend | ALC was below its $92.55 52-week high and above the $61.84 52-week low. The chart is range-bound until price and volume confirm a break from the mid-$60s area. | Medium |
| Risk level | Risk is medium-high because procedure demand can soften, launch spending and tariffs can pressure margins, currency can move reported results, and competition can challenge pricing or adoption. | High |
| AI confidence | High for audited and filed data, market-cap math, and stated guidance; medium for scenario analysis and technical trade setups. | High data confidence |
| Investment certainty | Medium certainty. ALC is a research candidate, not a universal buy, because execution and market valuation still determine the outcome. | Medium |
ALC AI stock forecast
The ALC AI stock forecast uses scenario ranges rather than a single price target. A three-year model using FY2025 core diluted EPS of $3.07 produced approximately $60.40 in a bearish case, $86.50 in a base case, and $110.30 in a bullish case. These outputs are conditional valuation scenarios, not predictions or recommendations.
$100 to $115
More likely if Surgical and Vision Care launches sustain growth, cataract and contact-lens demand remains healthy, core EPS compounds near 10 percent, margins expand despite tariffs, and investors assign a premium medical-technology multiple.
$80 to $90
More likely if sales grow around managements 5 percent to 7 percent constant-currency outlook, core EPS compounds near 7 percent, free cash flow remains solid, and the market applies a low-20s earnings multiple.
$55 to $65
More likely if procedure volumes weaken, new products miss adoption goals, tariffs or currency pressure margins, competition intensifies, or investors rerate the stock toward a high-teens earnings multiple.
ALC AI technical analysis
ALC AI technical analysis is a dated July 11, 2026 snapshot, not a live trading signal. The last available quote was $66.91 and the 52-week range was $61.84 to $92.55. Live 50-day and 200-day moving averages should be checked immediately before any trade because a dated static page cannot safely substitute for a current chart.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $66.91 | StockAnalysis quote snapshot at the stated cutoff. Confirm the live quote before acting. |
| Near support | $61.84 to $65 | The 52-week low and nearby mid-$60s trading area are a risk reference, not a guaranteed floor. |
| Near resistance | $70 to $75 | A sustained move above this zone on stronger volume would improve the short-term structure. |
| Long-term resistance | $92.55 | The 52-week high is a clear longer-term reference and needs fundamental and volume confirmation to reclaim. |
| Moving averages | Check live 50-day and 200-day values | No independently verified moving-average snapshot was available at this cutoff. Use a live chart to judge the trend. |
| Momentum and volume | Use volume confirmation | A breakout is more credible when volume is above the recent average and earnings or guidance support it. |
| Volatility | $61.84 to $92.55 52-week range | Clinical product news, guidance, macro conditions, and currency can materially reset expectations. |
| Invalidation | Sustained close below $61.84 | A decisive move below the 52-week low invalidates a range-support setup and calls for a fresh review. |
ALC AI trading strategy
The ALC AI trading strategy is a rules-based research framework, not personalized investment advice. Combine a current chart check with earnings releases, procedure volumes, launch adoption, margins, currency, tariffs, and position-size limits.
Wait for ALC to reclaim $70 to $75 with above-average volume, then confirm that live 50-day and 200-day moving averages support the move. Reassess after earnings and guidance.
Use a pre-defined loss limit. A sustained close below $61.84 or deteriorating guidance should invalidate the setup.
If price tests $61.84 to $65 without a new fundamental impairment, compare the reaction with surgical procedure trends, Vision Care growth, free cash flow, and tariff or currency updates.
Do not average down automatically. A break below the 52-week low or a negative earnings reset requires reassessment.
Track Surgical and Vision Care sales, Unity and Tryptyr adoption, constant-currency growth, core operating margin, free cash flow, net debt, buyback execution, and 2026 guidance.
Reduce confidence if growth depends on currency or short-term pricing while core margins, procedure volumes, and cash conversion weaken.
Investment research summary
Alcon earns money by supplying eye-care professionals and consumers with surgical systems, implants, consumables, contact lenses, and ocular-health products that address recurring clinical and vision needs.
The moat rests on clinical trust, regulatory know-how, surgeon training, installed equipment, product ecosystems, global distribution, and brands. It must be renewed through product innovation.
The thesis can fail if procedure volumes slow, surgeons or consumers resist new products, competitors gain share, tariffs and currency overwhelm pricing, or launch spending does not turn into durable cash returns.
Management is allocating capital to product launches, R&D, dividends, and a three-year buyback authorization of up to $1.5 billion. The scorecard is organic growth, margin discipline, cash conversion, and return on invested capital.
Aging populations, cataract procedures, myopia management, contact-lens use, dry-eye treatment, and technology upgrades can support demand, though reimbursement and health-system budgets affect timing.
The price implies confidence that earnings quality and launch momentum will improve. A margin of safety depends on separating GAAP from core earnings, testing free cash flow durability, and not assuming a premium multiple is permanent.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ALC price and 52-week range | $66.91; $61.84 to $92.55 range | StockAnalysis quote and statistics snapshot | July 11, 2026 |
| Market capitalization | $32.80 billion reported; $32.63 billion verified as $66.91 x 487.7 million shares | Alcon Q1 2026 interim report and financial_rigor.py | July 11, 2026 |
| FY2025 revenue | $10.401 billion, up 4.94 percent year over year | Alcon 2025 Form 20-F and Macrotrends cross-check | July 11, 2026 |
| FY2025 net income and free cash flow | $980 million net income and $1.728 billion free cash flow | Alcon FY2025 results and StockAnalysis cross-check | July 11, 2026 |
| Q1 2026 sales | $2.706 billion, up 10 percent reported and 6 percent constant currency | Alcon Q1 2026 results release | July 11, 2026 |
| Cash and debt, Q1 2026 | $1.659 billion cash and short-term investments; $5.262 billion total debt; $3.603 billion net debt | Alcon Q1 2026 interim report and StockAnalysis cross-check | July 11, 2026 |
| 2026 outlook | 5 percent to 7 percent constant-currency sales growth and 10 percent to 13 percent core diluted EPS growth | Alcon Q1 2026 interim report | July 11, 2026 |
| Valuation check | 40.31x TTM GAAP EPS, 1.49x book value, 19.12x free cash flow per share, 0.53 percent dividend yield | financial_rigor.py valuation verification | July 11, 2026 |
This ALC AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after earnings, product news, tariff or currency updates, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
